Lv0
0 积分 2022-08-25 加入
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
3个月前
已完结
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
4个月前
已完结
Imlunestrant: First Approval
5个月前
已完结
Comparison of design methods for a safety run-in phase of a phase II clinical trial
10个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
10个月前
已完结
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
11个月前
已完结
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer
11个月前
已完结
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates
1年前
已完结
皖公网安备34019202002308
